High plasma D-dimer level is associated with decreased survival in patients with lung cancer.

AIMS An elevated plasma D-dimer level indicates the activation of coagulation and fibrinolysis. In the present study, we investigated the association of pre-treatment haemostatic parameters (D-dimer, fibrinogen and prothrombin fragment 1+2) with clinicopathological parameters and outcome in patients with lung cancer. MATERIALS AND METHODS Plasma levels of D-dimer and other parameters were measured in 78 evaluable patients with lung cancer (60 non-small cell lung cancers, 18 small cell lung cancers). At diagnosis, 35 patients (44.9%) were locally advanced stage (IIIA/B) and 43 patients (55.1%) had metastatic disease (IV). Multivariate statistical analysis was carried out using Cox's proportional hazards model. The receiver operating characteristic curve was used to determine the cut-off values for D-dimer, fibrinogen and prothrombin fragment 1+2. RESULTS The median survival for all patients was 264 days (95% confidence interval 200-328 days). A significant association between the plasma levels of D-dimer and the response to chemotherapy was observed (P=0.03). With the univariate analysis, tumour stage, pre-treatment plasma levels of D-dimer, fibrinogen, platelet count, lactate dehydrogenase concentration and Karnofsky performance status were predictive for survival. With the multivariate analysis (P< or =0.1), the plasma level of D-dimer (P<0.001), tumour stage (P=0.01) and Karnofsky performance status (P=0.02) were identified as independent predictive factors. The median survival times were 405 days (95% confidence interval 165-644 days) and 207 days (95% confidence interval 146-267 days, P<0.001), respectively, for patients with a low D-dimer level (< or =0.65 microg/ml) and a high D-dimer level (>0.65 microg/ml). CONCLUSIONS Elevated plasma levels of D-dimer in patients with lung cancer are associated with decreased survival and a poor response to treatment. Pre-treatment for the D-dimer level may be useful in the prediction of survival and the response to treatment.

[1]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[2]  F. Turturro,et al.  Plasma Coagulation Markers in Patients with Solid Tumors and Venous Thromboembolic Disease Receiving Oral Anticoagulation Therapy , 2004, Clinical Cancer Research.

[3]  W. Henderson,et al.  Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75 , 1984, Cancer.

[4]  R. Seitz,et al.  Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[5]  W. Thompson,et al.  Angiogenic activity of fibrin degradation products is located in fibrin fragment E , 1992, The Journal of pathology.

[6]  Susanne M. Smorenburg,et al.  The effect of low molecular weight heparin on survival in patients with advanced malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Gralnick,et al.  Coagulation disorders in cancer. , 1996, Hematology/oncology clinics of North America.

[8]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[9]  M. Oya,et al.  High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. , 2001, Japanese journal of clinical oncology.

[10]  D. Ferrigno,et al.  Plasma levels of D‐dimer in lung carcinoma , 2003, Cancer.

[11]  E. Gabazza,et al.  Evaluating prethrombotic state in lung cancer using molecular markers. , 1993, Chest.

[12]  D. Berry,et al.  Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Ridgway Pf.  Tumours : wounds that do not heal. , 2002 .

[14]  G. Hawson,et al.  Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[15]  Ioannis Karydis,et al.  Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. , 2006, Lung cancer.

[16]  R. Bick.  Coagulation Abnormalities in Malignancy: A Review , 1992, Seminars in thrombosis and hemostasis.

[17]  A. Yılmaz,et al.  Prognostic significance of hemostatic parameters in patients with lung cancer. , 2004, Respiratory medicine.

[18]  J. Rak,et al.  Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. , 2006, Seminars in thrombosis and hemostasis.

[19]  A. Unal,et al.  A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer , 2004, Journal of thrombosis and haemostasis : JTH.

[20]  M. Yoshida,et al.  Prognostic significance of plasma D-dimer levels in patients with lung cancer. , 1997, Thorax.

[21]  D. Ferrigno,et al.  Haemostatic abnormalities in lung cancer: prognostic implications. , 1997, European journal of cancer.

[22]  C. Lewis,et al.  Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. , 2000, Cancer research.